



Pharma **POOL**

Dr. Michael E.

KAMARCK

Dr. Michael D.

KOWOLENKO

Joseph M. **MAHADY**

Cavan M. **REDMOND**

Douglas A. **ROGERS**

Wyeth Hires and
Promotes Executives

Wyeth, Madison, N.J., has announced a number of executive hires and promotions at its pharmaceuticals and consumer health divisions.



At Wyeth Pharmaceuticals, Collegeville, Pa., Michael E. Kamarck, Ph.D., has been promoted to executive VP, technical operations and product supply, from his previous role as senior VP, technical operations and product supply. In this new role, Dr. Kamarck is responsible for leading the effort to integrate Wyeth Pharmaceuticals' biotech and pharmaceutical operating units and align them with the division's commercial and R&D organizations.



Wyeth Pharmaceuticals has appointed Michael D. Kowolenko, Ph.D., to succeed Dr. Kamarck as senior VP, technical operations and product supply for the division's biotech operating unit. Dr. Kowolenko

was most recently senior VP, pharmaceutical operations and technology, at Biogen Idec.



Joseph M. Mahady has been promoted to president of Wyeth Pharmaceuticals, as well as a senior VP of Wyeth. Mr. Mahady was previously president, global business, with responsibility for all of Wyeth Pharmaceuticals' commercial businesses worldwide. He received a pharmacy degree from St. John's University College of Pharmacy and an MBA from Fairleigh Dickinson University.



Wyeth Consumer Healthcare, Madison, N.J., has promoted Cavan M. Redmond to president, with responsibility for the division's global operations. Mr. Redmond previously served as executive VP and general manager of the BioPharma business unit of Wyeth Pharmaceuticals. He received a bachelor's degree in political science from the University of Maryland and a master's degree in administration from The Johns Hopkins University.



Douglas A. Rogers has been appointed to the newly created position of president, U.S., and global new business, for Wyeth Consumer Healthcare. Mr. Rogers most recently was president of Wyeth Consumer Healthcare. He received a bachelor's degree in journalism and an MBA, both from Lehigh University.

Dr. John C. **LECHLEITER**

Lilly Names CEO Successor

Eli Lilly, Indianapolis, has named president

and chief operating officer John C. Lechleiter, Ph.D., to succeed retiring CEO Sidney Taurel, effective April 1. Mr. Taurel will continue as Lilly's chairman until the end of the year.

Dr. Lechleiter has been with Lilly for 28 years, and has served as president and chief operating officer of Lilly since October 2005. He continues his role as president of Lilly.

He received a B.S. summa cum laude in chemistry from Xavier University and studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he was granted his master's and doctorate degrees.

Kenneth L. **MURTHA**

AstraZeneca Expands
Operations VP Post



AstraZeneca, Wilmington, Del., has appointed Kenneth L. Murtha to the newly expanded role of regional supply VP, the Americas. Mr. Murtha was previously VP, business operations, for the United States. In addition to his North American responsibilities, Mr. Murtha now oversees distribution in Latin America and supply sites in Argentina, Brazil, Puerto Rico, and Mexico.

Mr. Murtha received a bachelor's degree in pharmacy from the University of Pittsburgh.

Biotech **POOL**

Dr. Raymond T.

BARTUS

Ceregene Announces
R&D Promotion



Ceregene, a San Diego-based biotechnology company focused on the development of gene therapies for neurodegenerative disorders, has promoted Raymond T. Bartus, Ph.D., to executive VP of clinical and preclinical R&D and chief operating officer. Previously, he was senior VP of clinical and preclinical R&D and chief operating officer.

Dr. Bartus has 30 years of experience in the biotech and pharmaceutical industry.

Dr. Mark **FROHLICH** Dendreon Names Medical Chief

Dendreon, a Seattle-based biotechnology company focused on oncology therapeutics, has promoted Mark Frohlich, M.D., to senior VP of clinical affairs and chief medical officer. Dr. Frohlich was previously VP of clinical affairs.

He received a B.S. in electrical engineering and economics from Yale University and an M.D. from Harvard Medical School.

Dr. François **MARTELET** Avax Appoints New CEO

Avax Technologies, Philadelphia, has named Dr. François Martelet president and CEO, replacing Richard Rainey, who is continuing as chief financial officer until at least May 31.

Dr. Martelet was most recently VP and global franchise head, oncology, at Merck.

He received a master's degree in business and a doctorate in medicine with distinction, both from Dijon University in France, as well as a degree in legal medicine from R. Descartes University School of Medicine in Paris.

Biopharmaceutical **POOL**

Michael D. **BECKER** VioQuest Appoints CEO



VioQuest Pharmaceuticals, a Basking Ridge, N.J.-based biopharmaceutical company focused on developing cancer therapeutics, has named Michael D. Becker president and CEO, replacing Daniel Greenleaf, who resigned to pursue other opportunities.

Mr. Becker was previously president and CEO of Cytogen, where he led the company's transformation from a research-driven biotechnology company into a product-focused specialty pharmaceutical company with a growing commercial presence in the U.S. oncology market.

He is chairman of BioNJ, a biotechnology industry advocacy group, which was founded in 1994.

Mr. Becker attended DePaul University in Chicago.

Dr. Martin A. **MATTINGLY** Trimeris Appoints CEO

Trimeris, Morrisville, N.C., a biopharmaceutical company specializing in the development and commercialization of antiviral therapies, has named Martin A. Mattingly, Pharm.D., as CEO. Dr. Mattingly most recently served as president and CEO of Ambrx Pharmaceuticals. He has also held positions at Agouron Pharmaceuticals, Pfizer, and Eli Lilly.

Dr. Mattingly received a doctor of pharmacy degree from the University of Kentucky.

Dr. Rainer **PABST** Peter **SEITH** Biotest Appoints U.S. Management Team



Biotest AG, a German biopharmaceuticals company specializing in plasma proteins, has named Rainer Pabst, Ph.D., as CEO of Biotest Pharmaceuticals, the U.S. division created as part of Biotest's acquisition of Nabi Pharmaceuticals' Nabi Biologics business unit. Dr. Pabst was previously managing director of Biotest Pharma GmbH. He has held positions at Bayer and Centeon.



Peter Seith, formerly a director of project management of Biotest Pharma GmbH, has been appointed VP of project management of Biotest Pharmaceuticals. In addition to heading project management for the Boca Raton, Fla.-based organization, Mr. Seith is serving as VP of corporate quality assurance for Biotest Pharma worldwide.

Dr. Lesley A. **STOLZ** Sunesis Appoints Business Development Head

Lesley A. Stolz, Ph.D., has been named VP, corporate and business development, of Sunesis Pharmaceuticals, a South San Francisco, Calif.-based clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule therapeutics for oncology and other life-threatening diseases.

Dr. Stolz was previously senior director,



business development of Aerovance, where she led efforts to partner the company's Phase II asset for uncontrolled asthma.

She received a B.S. from the University of Virginia and M.S. and Ph.D. degrees from the

University of Rochester.

Dr. Kleanthis G. **XANTHOPOULOS** Regulus Therapeutics Names CEO

Regulus Therapeutics, Carlsbad, Calif., has appointed Kleanthis G. Xanthopoulos, Ph.D., as president and CEO. Regulus is a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals formed to discover, develop, and commercialize therapeutics using microRNAs, substances believed to regulate the expression of a large number of human genes.

Dr. Xanthopoulos, a cofounder and former president and CEO of Anadys Pharmaceuticals, was most recently a managing director of Enterprise Partners Venture Capital.

An Onassis scholar, he received a B.Sc. in biology with honors from Aristotle University, as well as an M.Sc. in microbiology and a Ph.D. in molecular biology, both from the University of Stockholm.

Specialty **POOL**

Kathleen **BOZIWICK** Dr. Michael E. **LUSTY** Intranasal Adds to Management Team

Intranasal Therapeutics, Montvale, N.J., a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, has made two key additions to its management team.

Kathleen Boziwick has been appointed VP, commercial development. Ms. Boziwick previously served as director and team leader for Pfizer's product evaluation group focused on the allergy and respiratory, infectious disease, and vaccine sectors. She received an MBA from Pace University.

Michael E. Lusty, Ph.D., has been named VP, pharmaceutical development. Dr. Lusty was most recently VP, aerosol research and

development, of Kos Pharmaceuticals. He received a Ph.D. in physics from the University of St. Andrews, Scotland.

Timothy **SAXON**

Tris Pharma Names Business Development VP

Timothy Saxon has been named VP, business development, of Tris Pharma, a Monmouth Junction, N.J.-based company specializing in orally administered drug-delivery technologies. Mr. Saxon most recently served as a business development consultant in the biotechnology field.

At Tris, Mr. Saxon spearheads the company's out-licensing activities and manages opportunities to help the company enhance product life cycles and competitively differentiate its products. Before this, he worked for Wyeth as assistant VP of global business development.

Mr. Saxon received an MBA with distinction and top honors from Loughborough University Business School in England.

Dr. Whaijen **SOO**

Shire Human Genetics Business Gains R&D Head



Shire's Human Genetic Therapies business, based in Cambridge, Mass., has appointed Whaijen Soo, M.D., Ph.D., as senior VP, research and development. Dr. Soo was previously senior VP of medical

research of Biogen Idec. He completed undergraduate studies in chemistry at National Taiwan University. Before that, he spent 18 years at Roche.

Dr. Soo received a Ph.D. in biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco.

Dr. Michael **SWEENEY**

Depomed Names Product Development Head



Depomed, Menlo Park, Calif., has appointed Michael Sweeney, M.D., VP of product development. In addition to overseeing all aspects of product development, Dr. Sweeney is responsible for the commercial medical

affairs function of Depomed.

Most recently, Dr. Sweeney was VP of medical affairs of CV Therapeutics, where his leadership enabled the commercial preparation and successful launch of Ranexa in 2006. Before that, he spent 11 years at Pfizer.

Dr. Sweeney received an M.D. from Manchester University, as well as a postgraduate diploma in pharmacoepidemiology from the University of London. He also holds a postgraduate diploma in pharmaceutical medicine, and is a fellow of the Royal College of Physicians of Edinburgh.

Emerging **POOL**

Patrick T. **HIGGINS**

Pharmasset Names Marketing and Sales Manager



Pharmasset, Princeton, N.J., has named Patrick T. Higgins executive VP, marketing and sales. Mr. Higgins was recently VP, sales and marketing, virology, at Roche, and since 2006 has served as a consultant

to Pharmasset, a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing drugs to treat viral infections.

Mr. Higgins' initial responsibilities for Pharmasset's marketing and sales group include building a team to market clevudine upon its approval for treatment of chronic hepatitis B infection.

Mr. Higgins received a B.A. from Villanova University and an MBA from Seton Hall University.

CRO **POOL**

Dr. Victor **KIRI**

Parexel Names Pharmacoepidemiology Director

Parexel International has appointed Victor Kiri, Ph.D., to director of pharmacoepidemiology within the company's clinical research services business.

Dr. Kiri's responsibilities include advising clients in the design and execution of com-



parative observational studies, offering epidemiological analysis for compounds in development, and guiding strategic decisions regarding future areas of research and product development.

Most recently, Dr. Kiri managed epidemiology research of GlaxoSmithKline.

He received an M.Sc. degree in operational research from the University of Sussex and a Ph.D. from the University of Bradford.

Service **POOL**

Dr. Steven **GORDZIEL**

James "Fred" **PRUDEN**

PharmaDirections Adds to Executive Team

Two industry veterans have joined the executive team of PharmaDirections, a drug-development management firm based in Cary, N.C.



Steven Gordziel, Ph.D., has been appointed practice head of pharmaceutical development, leading efforts to expand the development of modified release and specialized dosage forms.

Dr. Gordziel has more than 30 years of experience in the pharmaceutical industry, most recently as VP, product development, of Hollis-Eden Pharmaceuticals.

He received a B.S. in pharmacy from the Philadelphia College of Pharmacy and a Ph.D. in pharmaceutical sciences from the University of Connecticut, Storrs.



James "Fred" Pruden has been named practice head of manufacturing operations and is expanding the company's capacity for rapid turnaround of clinical trial materials using PharmaDirections' proprietary virtual manu-

facturing systems.

Mr. Pruden has more than 35 years of experience in pharmaceutical manufacturing and compliance.

Most recently, he was VP of manufacturing operations of AAIPharma.

Medical-Education **POOL**

Rich **CARACIO**
 Bob **DONAHOE**
 Paul **KOREN**
 Peter **PAYERLI**
 Melissa **WARNER**

CME Restructures
 Management Team



CME LLC, Irvine, Calif., a division of CMPMedica, has reorganized its management team, naming Melissa Warner senior VP, general manager, and promoting Rich Caracio, Bob Donahoe, and Peter Payerli as VPs of education initiatives. CME offers a wide range of informational and educational resources for healthcare professionals, including live events and conferences, print supplements, multimedia home study products, and

Websites.

Mr. Caracio, Mr. Donahoe, and Mr. Payerli were previously executive directors of CME. Ms. Warner was most recently VP and general manager of the oncology and radiology divisions of CMPMedica U.S.

CME also has appointed Paul Koren executive director of education initiatives. Most recently, Mr. Koren was responsible for generating growth for the oncology division of CMPMedica U.S.

Beatrix **ERIKSEN**
 Marcy **HOLETON**
 Kathy **MISCHAK**
 Steve **SANBORN**
 Beth **SCHOLZ**

CMPMedica U.S. Makes
 Executive Promotions

CMPMedica U.S., the New York-based medical education unit of CMPMedica, London, has announced a number of promotions to the executive management team.



Beatrix Eriksen is now VP of research, marketing, and circulation. Ms. Eriksen previously served as group director of research and circulation at CMPMedica U.S.



Marcy Holeton was promoted to senior VP and general manager of the primary care and specialties businesses. Previously, Ms. Holeton was a group VP and general manager.

Kathy Mischak is now group publisher for oncology and radiology.

In her previous role at CMPMedica U.S., Ms. Mischak oversaw Diagnostic Imaging as the journal's publisher.

Steve Sanborn, who previously held the position of group production manager, is now group director of manufacturing and production.

Beth Scholz has been promoted to VP of the oncology and radiology divisions. Previously, Ms. Scholz was publisher of CMPMedica U.S.'s Oncology Publishing Group, which includes *Oncology* and *Oncology News International*.

Agency **POOL**

Vincent Dean **BOYCE**
 Meghan **REILLY**
 Robert **SADOWSKI**
 HealthEd Expands Staff

HealthEd, Clark, N.J., a developer of patient education programs for pharmaceutical and healthcare marketers, has added a number of professionals to its team.

Vincent Dean Boyce has been named senior interactive designer responsible for developing initiatives, contexts, frameworks, and interfaces for online and mobile interactive systems. He previously did freelance work for Siemens. He received a BFA in design and technology from Parsons School of Design and a master's of professional studies in interactive telecommunications from New York University.

Meghan Reilly has joined HealthEd as account coordinator. Ms. Reilly previously worked at Integrated Communications. She received a B.S. in marketing from the University of Scranton.

Target Pharma**VOICE** Readers

with your **DIRECT MAIL** or **E-MAIL** Marketing Campaign



- ▶ **35,000+ direct mail addresses**
- ▶ **60,000+ E-mail addresses**

To rent the PharmaVOICE mail or e-mail list,
 call 215-321-8656 to speak with Marah Walsh, (mwash@pharmavoice.com).

Read. Think. Participate.

www.pharmavoice.com

Robert Sadowski has been appointed manager, information technology. Before joining HealthEd, Mr. Sadowski was system administrator for Interbrand Corporation. He received a B.S. in computer technology from the New Jersey Institute of Technology.

Dave **BOYD**

Malinda **McFARLANE**

Chris **MYCEK**

Gavin **TWIGGER**

imc2 Expands Senior Management Team

Independent digital marketing agency imc2, Dallas, has added four marketing industry veterans to its senior management team.

Dave Boyd has been appointed general manager responsible for leading imc2's Procter & Gamble accounts. Previously, Mr. Boyd was VP and managing partner of Agency.com.

Malinda McFarlane has been named director of strategy. Ms. McFarlane has more than 15 years of experience developing and implementing digital marketing campaigns, brand vision, and strategy for a number of multi-billion dollar corporations in the consumer sector.

Chris Mycek has joined imc2 as VP, health and wellness. Mr. Mycek's previous experience includes senior VP of Digitas Health/Medical Broadcasting, where he helped establish relationships with key clients such as Eli Lilly, AstraZeneca, Amgen, Allergan, Genentech, Millennium, and Biogen Idec.

Gavin Twigger has been appointed group creative director dedicated to formulating and executing strategic creative concepts for imc2's Procter & Gamble accounts. Previously, Mr. Twigger was senior VP, executive creative director of Rapp Collins Worldwide, where he helped develop digital marketing for several high-profile consumer product, media, and financial companies.

Aradhana **DUGAR**

Lori **KEWIN**

Priscilla Field **KOZEL**

Lauren **ROACH**

Hillary **ZAUSMER**

Topin Announces Staff Additions

Topin & Associates, a full-service independent agency based in Chicago, has made a number of additions to its staff. Aradhana Dugar has been named senior account execu-



tive and is working on accounts for Fenwal Blood Technologies, Baxter BioPharma Solutions, and Teva Neuroscience. Previously, Ms. Dugar was an assistant account executive at The Hal Lewis Group. She received a B.S. in business administration and a B.A. in psychology from Carnegie Mellon University.

Lori Kewin has joined Topin as director of account service. Ms. Kewin most recently served as VP and account director of Goble & Associates. She received a BBA from Western Michigan University.

Priscilla Field Kozel has been appointed associate creative director. Ms. Kozel previously was with Goble & Associates. She received a B.A. from the University of Iowa.

As project manager at Topin, Lauren Roach is working on accounts for Ovation Pharmaceuticals, Fenwal Blood Technologies, and Baxter Healthcare. Previously, Ms. Roach was an account executive for Campbell-Ewald Advertising. She received a B.S. in TV, radio, film production from Syracuse University.

Hillary Zausmer has joined Topin as an account executive, working on the Baxter Medication Delivery account. Previously, Ms. Zausmer was an account executive for DraftFCB Advertising. She holds a B.A. in organizational studies from the University of Michigan.

Richard T. **MINOFF**

Dorland Announces CEO

Dorland Global, Philadelphia, has promoted Richard T. Minoff to CEO and president, succeeding agency founders Harry and Rita Sweeney, who had served as CEO and president, respectively. The chief operating officer position, which was also held by Ms. Sweeney, has been eliminated.

Mr. Minoff is responsible for leading the overall agency into its new position as part of Huntsworth Health, a division of

Huntsworth, the global communications company that acquired Dorland Global in March 2007. Previously, he was president of Dorland Global Health Communications.

He is a cum laude graduate of the University of Connecticut and received an MBA in management and business policy from the Robert H. Smith School of Business at the University of Maryland.

Diedrea **WHITE**

AbelsonTaylor Names Oncology Account Supervisor



Independent health-care agency Abelson-Taylor, Chicago, has appointed Diedrea White account supervisor for a global assignment in the oncology category.

Previously, Ms. White was group program director of Health Science Communications. She received a B.A. in journalism and French from Indiana University, Bloomington.

Technology **POOL**

Michael **MICKENS**

Chuck **PICCIRILLO**

Etrials Names New Managers



Etrials Worldwide, Morrisville, N.C., has appointed Michael Mickens VP of sales and client services and Chuck Piccirillo as VP of product development.

Mr. Mickens most recently was VP of worldwide sales and business development of Cerner. He received a B.S. in finance and marketing from Colorado State University.



Mr. Piccirillo has joined etrials from Hill-Rom's HealthCare IT Solutions business. He received a BSEE from Fairleigh Dickinson University. ♦

Send your personnel announcements to feedback@pharmavoice.com.